Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Table 1 Incidence of neuropathy in statin user and non-user group

				Propensity score-matched1
	Statin user, n (%)	Statin non-user, n (%)	P value	Statin user, n (%)	Statin non-user, n (%)	P value
2016
Neuropathy incidence	582/17413 (3.34)	477/17267 (2.76)	0.0017	579/17267 (3.35)	477/17267 (2.76)	0.0014
2017
Neuropathy incidence	562/18707 (3.00)	449/16882 (2.66)	0.0507	523/16882 (3.10)	449/16882 (2.66)	0.0160

¹Propensity score-matching was performed by including baseline age, gender and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS).

Table 2 Incidence of neuropathy in metformin user and non-user group

				Propensity score-matched1
	Metformin user, n (%)	Metformin non-user, n (%)	P value	Metformin user, n (%)	Metformin non-user, n (%)	P value
2016
Neuropathy incidence	914/30683 (2.98)	158/3922 (4.03)	0.0004	49/3922 (1.25)	158/3922 (4.03)	< 0.0001
2017
Neuropathy incidence	959/31624 (3.03)	143/4004 (3.57)	0.0635	64/4004 (1.60)	143/4004 (3.57)	< 0.0001

¹Propensity score-matching was performed by including baseline age, gender, and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS).

Table 3 Incidence of neuropathy in statin + metformin user and non-user group

				Propensity score-matched1
	Statin + metformin user, n (%)	Non-user, n (%)	P value	Statin + metformin user, n (%)	Non-user, n (%)	P value
2016
Neuropathy incidence	438/14524 (3.02)	83/2175 (3.82)	0.0452	71/2175 (3.26)	83/2175 (3.82)	0.3248
2017
Neuropathy incidence	472/16096 (2.93)	65/2040 (3.19)	0.5239	62/2040 (3.04)	65/2040 (3.19)	0.7868

¹Propensity score-matching was performed by including baseline age, gender, and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS).

Table 4 Logistic regression analyses for neuropathy occurrence in 2016 and 2017 Health Insurance Review and Assessment national patient sample data

			Propensity score-matched1
	OR	95%CI	OR	95%CI
2016
Statin use	1.22	1.07-1.38	1.22	1.08-1.38
Metformin use	0.73	0.61-0.87	0.30	0.21-0.42
Statin + metformin use	0.78	0.62-1.01	0.85	0.61-1.19
2017
Statin use	1.13	1.00-1.29	1.17	1.03-1.33
Metformin use	0.84	0.71-1.02	0.44	0.32-0.60
Statin + metformin use	0.92	0.70-1.21	0.95	0.66-1.38

¹Propensity score-matching was performed by including baseline age, gender, and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS). OR: Odds ratio; CI: Confidence interval.